Clinical trials: in Brazil
Non-small Cell Lung Cancer, NSCLC
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line…
- Trial name
- NCT06422143
- Testing
- Pembrolizumab, sac-TMT, Carboplatin
- Where
- 217 sites in United States, Argentina and 24 more
- Volunteers
- 851 people
- Sponsor
- Merck Sharp & Dohme LLC
Atherosclerotic Cardiovascular Disease, Overweight
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
- Conditions
- Atherosclerotic Cardiovascular Disease, Overweight, Obesity
- Trial name
- MARITIME-CV (NCT07037433)
- Testing
- Maridebart Cafraglutide
- Where
- 783 sites in United States, Argentina and 34 more
- Volunteers
- 12,800 people
- Sponsor
- Amgen
Idiopathic Inflammatory Myopathies
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
This study is open to adults aged 18 and older who have a condition known as active idiopathic inflammatory myopathy (IIM) or myositis. People can participate if they have a specific type of myositis.
- Trial name
- VERANDA™-IIM (NCT07789015)
- Testing
- Nerandomilast
- Where
- 158 sites in United States, Argentina and 24 more
- Volunteers
- 270 people
- Sponsor
- Boehringer Ingelheim
Advanced (Unresectable or Metastatic) Melanoma
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
This is a randomised, multicentre, multinational, double-blind, integrated study to sompare the pharmacokinetics, efficacy, safety, and immunogenicity of MB11 versus Opdivo® in subjects with previously untreated advanced…
- Trial name
- NCT07221734
- Testing
- MB11 (Proposed Nivolumab Biosimilar), EU-Opdivo®, US- sourced Opdivo®
- Where
- 86 sites in Bosnia and Herzegovina, Brazil and 11 more
- Volunteers
- 632 people
- Sponsor
- mAbxience Research S.L.
Carcinoma, Renal Cell
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC). A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy.
- Trial name
- NCT07489495
- Testing
- Belzutifan, Zanzalintinib
- Where
- 106 sites in United States, Argentina and 17 more
- Volunteers
- 758 people
- Sponsor
- Merck Sharp & Dohme LLC
Frontotemporal Dementia, FTD
A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes
PBFT02 is a gene therapy for frontotemporal dementia intended to deliver a functional copy of the GRN gene to the brain. This study will assess the safety, tolerability and efficacy of this treatment in patients with…
- Conditions
- Frontotemporal Dementia, FTD, FTD-GRN, Dementia Frontotemporal
- Trial name
- upliFT-D (NCT04747431)
- Testing
- PBFT02
- Where
- 10 sites in United States, Australia and 3 more
- Volunteers
- 30 people
- Sponsor
- Passage Bio, Inc.
Non-small Cell Lung Cancer
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins…
- Trial name
- NCT05668988
- Testing
- sunvozertinib, Pemetrexed+carboplatin
- Where
- 154 sites in United States, Argentina and 13 more
- Volunteers
- 324 people
- Sponsor
- Dizal Pharmaceuticals
Inherited Retinal Degeneration, Retinitis Pigmentosa
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
This is an international, multicenter study with two components: Registry A standardized genetic screening and a prospective, standardized, cross-sectional clinical data collection Enrollment is open to all genes on the RD Rare…
- Trial name
- Uni-Rare (NCT05589714)
- Where
- 36 sites in United States, Australia and 12 more
- Volunteers
- 1,500 people
- Sponsor
- Jaeb Center for Health Research
Polycythemia Vera
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
The purpose of this study is to evaluate the efficacy and safety of sapablursen when added on to current standard of care (SOC) for Polycythemia Vera (PV) therapy.
- Trial name
- INTREPID (NCT07429266)
- Testing
- Sapablursen
- Where
- 38 sites in United States, Australia and 7 more
- Volunteers
- 250 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
HIV - Human Immunodeficiency Virus
Multiple Interventions With Distinct Anti-reservoir Activities in People on Antiretroviral Treatment
Contemporary ART fails to eradicate the HIV-1 virus from PWH, resulting in a rebound in viremia within days to weeks after cessation of ART.
- Trial name
- NCT07903441
- Testing
- Multiple therapeutic interventions
- Where
- Brazil
- Volunteers
- 70 people
- Sponsor
- Federal University of São Paulo
Non-small Cell Lung Cancer
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous…
- Trial name
- NCT06692738
- Testing
- Rilvegostomig, Pembrolizumab, Carboplatin
- Where
- 333 sites in United States, Argentina and 24 more
- Volunteers
- 1,160 people
- Sponsor
- AstraZeneca
Muscle Invasive Bladder Cancer
Radical CystEctomy or RaDio-chEMotherapy as Preferred Treatment for invasivE blaDder Cancer
Your text is mostly clear and well-structured. Here's a slightly polished version for improved clarity and flow: This is a randomized, non-inferiority study comparing radiochemotherapy to radical cystectomy in patients with…
- Trial name
- REDEMPTED (NCT07008833)
- Testing
- Radiochemotherapy, Radical cystectomy
- Where
- Brazil
- Volunteers
- 336 people
- Sponsor
- Brazilian Clinical Research Institute
Lupus Nephritis
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis
- Trial name
- IRIS (NCT05138133)
- Testing
- Anifrolumab
- Where
- 164 sites in United States, Argentina and 22 more
- Volunteers
- 363 people
- Sponsor
- AstraZeneca
Invasive Mold Infections
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
The purpose of this study is to evaluate the efficacy and safety of fosmanogepix (administered IV or oral) for the treatment of adult patients with invasive mold infections.
- Trial name
- NCT06925321
- Testing
- Fosmanogepix IV infusion, Standard of care antifungal therapy, Fosmanogepix oral tablet
- Where
- 90 sites in United States, Australia and 13 more
- Volunteers
- 234 people
- Sponsor
- Basilea Pharmaceutica
Interstitial Lung Diseases
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
This study is open to adults with fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). People can join the study if they have been diagnosed with this condition within the last 3 years and are…
- Trial name
- NCT07540988
- Testing
- Nerandomilast
- Where
- 162 sites in United States, Argentina and 18 more
- Volunteers
- 466 people
- Sponsor
- Boehringer Ingelheim
Kidney Disease, Chronic
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study.
- Trial name
- NCT06531824
- Testing
- BI 690517, Empagliflozin
- Where
- 562 sites in United States, Argentina and 18 more
- Volunteers
- 8,371 people
- Sponsor
- Boehringer Ingelheim
Geographic Atrophy Secondary to Age-related Macular Degeneration
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who…
- Trial name
- GALE (NCT04770545)
- Testing
- PEGCETACOPLAN (APL-2)
- Where
- 175 sites in United States, Argentina and 13 more
- Volunteers
- 792 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
This open-label, Phase I study will assess the safety and tolerability of surovatamig and characterise its PK and PD following subcutaneous administration to participants with RA or SLE.
- Trial name
- ASSURO (NCT07201558)
- Testing
- Surovatamig
- Where
- 35 sites in United States, Australia and 8 more
- Volunteers
- 48 people
- Sponsor
- AstraZeneca
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib.
- Trial name
- CHONQUER (NCT06127407)
- Testing
- Ivosidenib 500mg
- Where
- 115 sites in United States, Australia and 15 more
- Volunteers
- 156 people
- Sponsor
- Servier Bio-Innovation LLC
Generalized Myasthenia Gravis
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
This study is researching the experimental drugs called pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on patients with generalized Myasthenia Gravis (gMG).
- Trial name
- NIMBLE (NCT05070858)
- Testing
- Pozelimab + Cemdisiran, Cemdisiran, Pozelimab
- Where
- 116 sites in United States, Belgium and 17 more
- Volunteers
- 288 people
- Sponsor
- Regeneron Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.